Evaluation of Dermatologic Adverse Events Associated with Aromatase Inhibitors: Insights from the FAERS Database

    May 2025 in “ Frontiers in Pharmacology ”
    Yuanyuan Wu, Q. Huang, Zhan-Yang Luo … Sheng Liu
    Studysummary In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Art of Prevention: The Importance of Dermatologic Care When Using Aromatase Inhibitors International Journal of Women’s Dermatology · 2021
    2. Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer JAMA Dermatology · 2018
    3. The Role Of Estrogen In Cutaneous Aging And Repair Maturitas · 2017

    Related research 1

    1. Multidimensional Assessment of Adverse Events of Finasteride: A Real-World Pharmacovigilance Analysis Based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024 medRxiv (Cold Spring Harbor Laboratory) · 2024